MTOR and neoplasm: Taken together, high MAEL expression was identified as an independent indicator of poor benefits from ICI-based therapies over VEGFR/mTOR inhibitors in advanced ccRCCs, potentially mediated by tumor-infiltrating immune cells and the expression of PD-1 and CTLA-4 rather than PD-L1.